|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results suggested that E2F1 activated SNHG3 and promoted cell proliferation and migration in NSCLC via transforming growth factor-β pathway and interleukin-6/janus-activated kinase 2/signal transducer and activator of transcription 3 pathway, which implied that SNHG3 may be a biomarker for the treatment of patients with NSCLC.
|
31602642 |
2020 |
|
Malignant neoplasm of breast
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together these data led to the hypothesis that Fgf13 is critical for breast cancer metastasis, and that upregulation of Fgf13 may partially explain how E2F1 promotes breast cancer metastasis.
|
31341204 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, the expression of the cell proliferation-related proteins E2F1, Ki-67, and cancer related protein cytokeratin 19 and Cox-2 increased in response to combined treatment with NDMA and ESP.
|
30943209 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Treatment of E2F1/MTA1-positive, highly aggressive, circulating melanoma cells and orthotopic pancreatic tumors with argatroban prevents metastasis and cancer relapses <i>in vivo</i> through perturbation of the E2F1:MTA1/HAS2 axis.
|
30867845 |
2019 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Recent studies have demonstrated the existence of multiple copies of E2F1 gene in melanoma specimens which could explain the deregulated E2F1 activity in this type of cancer.
|
31142321 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This study shows for the first time that E2F1 has a cancer protective role in oncogenic BRAF-activated melanoma cells and that loss of E2F1 can allow disease progression through a novel mechanism of E2F1-mediated MYLK regulation.
|
31124185 |
2019 |
|
Malignant Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
To date, this is the first preclinical study evaluating the effect of genetic deletion of E2F-1 in colorectal malignancies driven by PTEN deficiency.
|
30206933 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Ribosomal protein uL3 targets E2F1 and Cyclin D1 in cancer cell response to nucleolar stress.
|
31659203 |
2019 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Dephosphorylated Rb suppressed E2F1 activity and then suppressed cancer stemness by inactivating c-Myc.
|
31831874 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Downregulation of SRPK2 promotes cell cycle arrest though E2F1 in non-small cell lung cancer.
|
31833327 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together, our study firstly confirmed a potential synergy between KRAS and MDM4/E2F1 which are p53/RB inactivators in non-small cell lung cancer, and identified miR-1205 as a potent destructor of this synergy, making miR-1205 function as a tumor suppressor in vitro and in vivo.
|
30906631 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Furthermore, mechanistic studies showed that the CDK4-pRB-E2F1 pathway was involved in NSCLC.
|
31190865 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Transcription factor E2F1 positively regulates interferon regulatory factor 5 expression in non-small cell lung cancer.
|
31692554 |
2019 |
|
melanoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We show for the first time that low E2F1 levels in BRAF<sup>V600E</sup> melanomas are associated with lymph node metastasis.
|
31124185 |
2019 |
|
melanoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
E2F1 CNV was measured in genomic DNA isolated from blood of 552 patients diagnosed with melanoma and 520 healthy subjects using TaqMan Copy Number Assays.
|
31142321 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Together, our study firstly confirmed a potential synergy between KRAS and MDM4/E2F1 which are p53/RB inactivators in non-small cell lung cancer, and identified miR-1205 as a potent destructor of this synergy, making miR-1205 function as a tumor suppressor in vitro and in vivo.
|
30906631 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The transcription factor, E2 promoter binding factor 1 (E2F-1), exhibits tumor promoter or suppressive functions depending on cellular type and tissue context, but its role in the progression and development of colorectal carcinogenesis was largely unknown.
|
30206933 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
The mRNA expression levels of <i>E2F1/3/5/8</i> were found to be significantly upregulated in patients with OC and were obviously associated with tumor stage for OC.
|
30967995 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In HCC specimens, E2F1 expression was much higher in tumor than in non-tumor tissues, and was significantly related to Edmondson-Steiner grade, overall as well as tumor-free survival.
|
30600477 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
High E2F1 expression was detected in 40% of the cases, and it was associated with tumor size, histologic grade, and tumor stage (p < 0.001 for each).
|
30684846 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin.
|
30733337 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Retinoblastoma is a pediatric solid tumor of the retina activated upon homozygous inactivation of the tumor suppressor <i>RB1</i> VCN-01 is an oncolytic adenovirus designed to replicate selectively in tumor cells with high abundance of free E2F-1, a consequence of a dysfunctional RB1 pathway.
|
30674657 |
2019 |
|
Breast Carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Together these data led to the hypothesis that Fgf13 is critical for breast cancer metastasis, and that upregulation of Fgf13 may partially explain how E2F1 promotes breast cancer metastasis.
|
31341204 |
2019 |
|
Liver carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Results:</b> E2F1 with its surrounding regulatory links were identified to play different key roles in the HCC risk factor dysregulation mechanisms.
|
31729887 |
2019 |
|
Liver carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Finally, murine and human HCC data indicate significant correlations of STMN1 expression with E2F1/TFPD1 and with KPNA2 expression and their association with poor prognosis in HCC patients.
|
31783876 |
2019 |